Business
Harvest One Phase II Clinical Trials on Satipharm CBD GelPell® Published in Peer-Reviewed Medical Journal
Harvest One Phase II Clinical Trials on Satipharm CBD GelPell® Published in Peer-Revi...
About this update from Delivra Health Brands Inc
[{"type":"text","content":"\n\n\n\nHarvest One Phase II Clinical Trials on Satipharm CBD GelPell® Published in Peer-Reviewed Medical Journal\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, Aug. 13, 2019\n\n\n\nVANCOUVER, Aug. 13, 2019 /CNW/ - Harvest One Inc. (\"Harvest One\" or the \"Company\") (TSXV: HVT; OTCQX: HRVOF), through its wholly-owned subsidiary Satipharm Ltd. (\"Satipharm\"), today announced positive results of a Phase 2 clinical trial of its CBD GelPell® capsules in the management of Treatment Resistant Epilepsy (TRE) have been published in Epilepsy & Behaviour, a bimonthly peer-reviewed medical journal covering behavioral aspects of epilepsy.\n\n \n \n\n \nHighlights include;\nPhase 2 open label clinical trial is aimed at measuring safety and efficacy of Satipharm CBD capsules for reducing seizure frequency in children with refractory, or treatment-resistant, epilepsy The median reduction of monthly seizures was -82% in the 12-week treatment period in treatment-resistant children when added to current medications 56% who started the treatment had a reduction of at least 50% in total number of seizures during the entire treatment period, compared to observation 73% were rated as \"very much improved/improved\" in overall condition on the Caregiver Global Impression of Improvement scale 82% were rated as \"very much reduced/reduced\" A mean 73.4% reduction from baseline monthly seizure frequencies was observed Two patients were fully seizure-free within 5 weeks of treatment An additional seven patients reported >50% seizure frequency reductionA fulsome description of the study and results can be found in the Harvest One background document available on our website at https://www.harvestone.com/portfolio/satipharm/#clinical-trials\n\"The results of our second stage of clinical trials on our Satipharm 50mg CBD GelPell® products are very encouraging for the patients we serve, our shareholders and our company\" said Grant Froese, Chief Executive Officer of Harvest One. \"We continue to be focused on the best in class health, wellness, an...